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to examine what we mean by remission, stability and pro-
gression of DN in the modern era.
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Introduction: obesity, diabetes and CKD—a 
cardio‑metabolic tsunami
The rapidly rising incidence of diabetes mellitus (DM) world-
wide is reputed to impact over 380 million people [1]. Table 1 
shows the current and predicted incidences of chronic kidney 
disease (CKD), DM, and patients with DM that have reached 
end-stage kidney disease (ESKD). China now has the highest 
rates of number of people with DM, around 98.4 million, fol-
lowed by India with 65.1 million and then the USA [2].
DM is the fifth cause of morbidity and mortality world-
wide [3], and the most common cause of ESKD in the 
Western world [4]. The European Renal Association (ERA-
EDTA) registry data showed that ten countries across 
Europe had an increase of 11.9 % per year of type 2 DM 
(T2DM) patients starting renal replacement therapy (RRT) 
[5].
T2DM increasingly arises in a younger and more obese 
population with metabolic syndrome [14] whose natural 
history is currently unknown but predicted to lead to full 
insulin resistance with a decline in renal function leading 
to CKD with proteinuria. The increasing rates of global 
obesity are a major drive in the development of diabetes, 
CKD and cardiovascular disease (CVD), representing a 
major health and health-economic burden to the developed 
and developing worlds. However, a significant proportion 
of patients with DM and CKD stage 3a/3b do not progress 
to ESKD and either stabilise with their current treatment 
Abstract The consensus management of diabetic 
nephropathy (DN) in 2015 involves good control of glycae-
mia, dyslipidaemia and blood pressure (BP). Blockade of 
the renin–angiotensin–aldosterone system using angioten-
sin-converting enzyme inhibitors, angiotensin-2 receptor 
blockers or mineralocorticoid inhibitors are key therapeutic 
approaches, shown to be beneficial once overt nephropathy 
is manifest, as either, or both, of albuminuria and loss of 
glomerular filtration rate. Some significant additional clini-
cal benefits in slowing the progression of DN was reported 
from the Remission clinic experience, where simultaneous 
intensive control of BP, tight glycaemic control, weight 
loss, exercise and smoking cessation were prioritised in 
the management of DN. This has not proved possible to 
translate to more conventional clinical settings. This review 
briefly looks over the history and limitations of current 
therapy from landmark papers and expert reviews, and 
following an extensive PubMed search identifies the most 
promising clinical biomarkers (both established and pro-
posed). Many challenges need to be addressed urgently as 
in order to obtain novel therapies in the clinic; we also need 
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therapies or die from their significantly higher cardiovas-
cular mortality risks before RRT is needed [4, 15]. Analy-
sis of the baseline characteristics of the Study of Heart and 
Renal Protection (SHARP) study showed the importance 
of primary renal disease leading to CKD [16]. The highest 
mortality overall is seen in patients with DM with a peak in 
mortality occurring prior to reaching ESKD.
The UK renal registry reported a mortality of 30 % in 
DM on RRT aged 18–44 years at 5 years: much higher than 
the 11 % observed in non-diabetic patients [17]. Following 
5 years of RRT, 34 % of non-diabetic patients aged 45–64 
died compared with 51 % in the DM group. The median 
life expectancy in non-diabetic patients requiring RRT aged 
<45 years was reported by the UK renal registry as 9 years 
more than in patients with DM of the same age. Thus, a 
further decade of life lost in this group of patients, many of 
whom, because of associated co-morbidities, are not prom-
ising candidates for pancreas and/or renal transplants.
Mahmoodi’s meta-analysis of >1 million people 
showed an association between all-cause and cardiovascu-
lar mortality and CKD in non-hypertensive and hyperten-
sive people with low GFRs and raised albumin–creatinine 
ratio (ACR). Patients with CKD alone had an all-cause 
and cardiovascular mortality, respectively, of 4.1 and 
0.9 %, while those with CKD and hypertension had an 
all-cause and cardiovascular mortality, respectively, of 15 
and 6.8 %. A subsequent meta-analysis looking at CKD 
with or without diabetes found similar relative risks of 
mortality between these two groups, thereby emphasising 
the importance of CKD as a major driver for mortality in 
these populations [18].
The degree of albuminuria has long been used to deter-
mine progression of DN with Adler reporting an annual 
incidence of people with diabetes progressing from nor-
moalbuminuria to microalbuminuria (2.0 %/year) to 
macroalbuminuria (2.8 %/year) and to ESKD (2.3 %/year) 
[19]. This is otherwise known as the “classical progres-
sion paradigm”, with mortality increasing at each stage 
(3.0, 4.6, 19.2 %/year, respectively). The decline in GFR 
has previously been thought to mirror changes in albumi-
nuria in DN; however, there are increasing reports that the 
decline in GFR may occur irrespective of the degree of 
albuminuria in a non-proteinuric DN phenotype [20]. It 
is, however, well established that the presence of albumi-
nuria and GFR independently and additively contribute to 
the cardiovascular and renal risk [21]. The alarming rates 
of disease incidence and progression continue despite the 
deployment of all current treatments and while achieving, 
in many cases, significant reductions in proteinuria require 
us to re-look at this well-known disease.
The basic challenge: treating the whole patient 
by looking beyond renal endpoints
The pathophysiology, history, effects and limitations 
of RAAS blockade
The mechanisms behind the pathophysiology of DN are 
complex and continue to be incompletely understood. 
Both metabolic (hyperglycaemia) and haemodynamic per-
turbations interact synergistically [22, 23] and have been 
reported to activate local RAAS resulting in increased 
angiotensin-2, reactive oxygen species (ROS), inflamma-
tion, expression of transforming growth factor-β (TGF-β) 
and dysregulation of different vascular growth factors such 
as the VEGF-A (upregulated in the initial phase of the 
disease) and the angiopoietin/Tie-2 system (with excess 
of angiopoietin-2 over angiopoietin-1) [24] (Fig. 1). This 
would otherwise be known as the classical pathway of DN 
where the hallmark features of thickening of the glomeru-
lar basement membrane, mesangial expansion and glo-
merulosclerosis are classically seen on renal biopsy [25] 
in combination with albuminuria and GFR decline. Mauer 
had described these renal biopsy changes in 285 people 
with T1DM with normoalbuminuria who had been given 
enalapril, losartan or placebo. In this study, formal GFRs 
and a repeat renal biopsy were undertaken to determine 
any histological changes between those on different ACEi/
ARB treatments. This small study showed the decline in 
GFR and the change in mesangial fractional volume of 
each glomerulus determining the degree of mesangial 
expansion. They found the changes were comparable in all 
groups [26], and thus, albuminuria was insensitive to these 
changes.
The risk of renal biopsy has prevented further larger 
studies performing this procedure on those without protein-
uria, and hence, it is unclear when the classical underlying 
Table 1  Predictions of population incidences of USA and UK [6–13]
Worldwide DM 1980–1990 2010–2020
153 million 472 million
USA
CKD 19 million >26 million
DM 5.8 million 24 million
ESKD with DM 17,727 48,215
UK
CKD 1.7 million 3.5 million
DM 2.9 million 5 million
ESKD with DM 870,000 1.7 million
Europe
CKD 59.3 million 65.9 million
DM 66.8 million 68.9 million
ESKD with DM 6.6 million 6.8 million
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histological changes occur or alter with renal function 
decline or proteinuria. The success of a DN animal model 
is that which has developed these histological features 
and whereby treatments act to reverse them; however, the 
problem therein lies that the existing models of DN do not 
develop albuminuria or have this without the histological 
features seen in man. Interestingly, advanced renal dam-
age has been reported in a study looking at nephrectomised 
cancer renal biopsies in those with T2DM without overt 
proteinuria suggesting that these changes may occur with 
GFR decline and worsen with the presence of proteinuria 
[20]. Other studies have attempted to reassess the features 
seen on the DN renal biopsy, and an increased heterogene-
ity within the histology of those with DN has been reported 
with the severity of glomerulopathy, tubulointerstitial fibro-
sis and arteriolar hyalinosis in those with microalbuminu-
ria quantified in the Tervaert’s histopathological classifi-
cation [25, 27, 28]. This clearly illustrates that the simple 
paradigm of progression once depicted is far more complex 
than initially thought.
More recently, there has been appreciation for the role 
of inflammation in the progression of DN. The mechanisms 
employed are poorly understood with reports of an increase 
in inflammatory cytokines (MCP-1, TNF-α) and mononu-
clear infiltrates in the glomeruli and tubulointerstitium that 
contribute to the progression of DN [29, 30]. Peroxisome 
proliferator-activated receptors-γ (PPAR-γ) (glitazones) 
agonists have been reported to be reno-protective in experi-
mental model of diabetes and in people with diabetes via 
their anti-inflammatory actions, in a metabolic independent 
manner [31, 32].
The RAAS has multiple roles in promoting progression 
of all renal diseases, particularly in DN [33]. The block-
ade of RAAS in animal and in vitro studies have shown a 
down-regulation of TGF-β, AGE, ROS, NADPH oxidase, 
RAGE expression and collagen IV (Col4) production—all 
leading to a reduction in mesangial expansion, glomerulo-
sclerosis, inflammation and tubulointerstitial fibrosis [34–
39]. These findings have further fuelled the desire to block 
RAAS as the sole treatment for DN.
Numerous studies have demonstrated since the 1980s 
how good blood pressure (BP) and strict glycaemic control 
decrease cardiovascular mortality in patients with DM and 
renal impairment [4, 19, 40]. The treatment of patients with 
DM with CKD was revolutionised in the 1990s, with most 
cited landmark papers such as the Captopril study in type 1 
DM (T1DM) reporting the loss of creatinine of 11 % from 
84 ml/min (~9 ml/min/year) versus 17 % from 79 ml/min 
(~13 ml/min/year) without captopril [41]. The Reduction of 
Endpoints in Non-insulin-dependent DM in the Angioten-
sin-2 Antagonist Losartan study (RENAAL) [42] simulta-
neously published with the Irbesartan Diabetic Nephropa-
thy Trial (IDNT) both showed a decrease in GFR decline or 
a delay in the doubling of creatinine and a reduction in pro-
teinuria in the ARB arm [43]. The possibility of preventing 
renal progression with eliminating this residual proteinuria 
with further agents suggested a further benefit by achieving 
complete RAAS blockade.
Earlier stage DN: normoalbuminuria to proteinuria, 
microalbuminuria to proteinuria
A delay in progression from microalbuminuria to overt 
proteinuria was described since 1995 with earlier stud-
ies focused on determining the significance of increasing 
proteinuria [44, 45]. Subsequently, Perkins showed factors 
associated with regression rather than progression of pro-
teinuria. The DCCT/EDIC study showed 28 % of micro-
albuminurics became macroalbuminuric with 15 % sus-
taining a loss of GFR and 4 % leading onto ESKD [46]. 
The introduction of RAAS blockade reduced proteinuria; 
regression rates to normoalbuminuria were 40 %, thus 
emphasising the relative insensitivity of albuminuria as a 
marker of progression in DN [47].
Undeniably, GFR decline occurs more rapidly in the 
presence of overt or nephrotic range proteinuria [48]; how-
ever, there has been a lack of appreciation of the degree of 
GFR decline occurring with minimal albuminuria. The loss 
of GFR is increasingly being reported in diabetic patients 
with normoalbuminuria, again illustrating how treatments 
targeting the resolution of albuminuria may already be too 
late in the disease or not work at all [49, 50]. In addition, 
formulae used to determine GFR are not sensitive at lev-
els of GFR >90 ml/min. The limitations of this formula 
are also apparent within the acute kidney injury arena 
where people with normal renal function without protein-
uria undergo a substantial rapid decline in renal function 
Fig. 1  Pathophysiology of DN
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secondary to an insult that may range from sepsis to drug 
induced that is not identified until the decline reaches lev-
els the formula identifies as low [51]. The modification of 
diet in renal disease (MDRD) formula has been established 
as having a higher sensitivity in GFR <60 ml/min with the 
chronic kidney disease epidemiology (CKD-EPI) formula 
reported to be more sensitive at higher GFRs; however, 
fundamentally the formulae are dependent on creatinine 
as the gold standard sensitive marker of renal injury. This 
marker, however, is non-specific to the type of histological 
injury. The laborious iohexol/inulin methods are employed 
in cases where true GFR is fundamental in providing drug 
treatments such as chemotherapy or for donors prior to liv-
ing kidney donation [52] and may detect decline in renal 
function; however, these are seldom used to assess the renal 
function in those with DN.
The introduction of RAAS blockade at this early stage 
of DN may not provide any benefit and emphasises the 
urgent need for more sensitive markers to detect early 
stage DN. This also challenges the simple paradigm of 
albuminuria leading to GFR loss and steady progression 
that may be conceptually too simplistic for such a complex 
disease.
Combining RAAS blockade with other, mainly 
cardioprotective, interventions
Dual blockade of RAAS was done using different agents 
in a number of studies with differing effects on the surro-
gate endpoint trials have adopted (Table 2). The safety of 
dual blockade was brought into question in these studies 
where new therapies are additive to existing ACEi/ARB 
therapy. The use of this combination in T2DM patients 
continues to be controversial and currently is not rec-
ommended. The effects of aliskiren alone have not been 
assessed as trials conducted with new agents currently act 
as adjuncts to RAAS blockade rather than alternatives to 
ACEi/ARB.
Intensification of therapies with RAAS blockade
The importance of a multistrategy approach with RAAS 
blockade led to the Steno-2 study [56], whereby intensive 
glycaemic and BP control was achieved. Smoking cessa-
tion, weight loss and a reduction in dietary sodium intake 
were additionally maintained. The results supported a mul-
tifactorial approach [56, 57] to achieve lower cardiovascu-
lar (CV) events and mortality in the intensely monitored 
group after 13.3 years [58]. A multimodal strategy approach 
to the management of DN is supported by the Remission 
clinic [59]. Dual RAAS inhibition was employed with 
intensified BP control, statin use, smoking cessation and 
implementation of a healthy lifestyle. The median follow-
up was 4 years and suggested that a multidrug approach in 
the treatment of CKD could slow the progression of CKD 
in T2DM and non-diabetics, similar to the Steno-2 study 
[56]. The Remission clinics had a median decline of −0.17 
versus −0.56 ml/min/1.73 m2/year of GFR in the intensive 
versus conventional treatment groups. BP decreased and 
a 50 % decline in urinary proteinuria from baseline levels 
was seen. Intensive monitoring avoided a rise in hyper-
kalaemic events supporting the use of this treatment strat-
egy in T2DM with hypertension and normoalbuminuria, 
similar to the Bergamo Nephrologic Diabetes Complica-
tions Trial (BENEDICT); however, all the patients in the 
BENEDICT trial were hypertensive to begin with [60]. The 
BENEDICT trial initially showed that trandolapril delayed 
the onset of microalbuminuria in T2DM with normoalbu-
minuria and hypertension.
Previous studies suggest a reduction in CV endpoints 
and mortality in all patients with diabetes adhering to a 
diastolic BP of <80 mmHg [61–63]. Whether a systolic BP 
of <130 or <140 mmHg has additional benefits on CVD and 
mortality remains unknown [61]. Systolic BP <125 mmHg 
was reported to be deleterious in the MDRD study and in 
diabetic patients >70 years of age [64–66]. To achieve sys-
tolic BP <130 mmHg requires an intense approach seen in 
Table 2  Outcome of landmark studies with RAAS blockade
Trial AVOID [53] ALTITUDE [50] VA NEPHRON D [54] Aldosterone antagonists [55]
Agent Aliskiren Aliskiren ACEi (Lisinopril) Aldosterone antagonist
Combined ACEi/ARB ARB (Losartan) ARB (Irbesartan) ARB (Losartan) ACEi/ARB (Lisinopril/Losartan)
Reduction of blood pressure Yes Yes Yes Yes
Decrease in the reduction in GFR Yes (−2.4 mls/min) Trial terminated No effect Yes (13 % less than placebo)
Anti-proteinuric effect Yes Yes Yes Yes
Effect on CV mortality No effect Increased events No effect Not powered
Hyperkalaemic events Same as placebo Increased Increased Increased
Acute kidney injury Same as placebo Increased Increased Same as placebo
Progression to ESKD No effect Trial terminated No effect Not powered
Number of patients 599 8561 1448 81
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both the Remission and Steno-2 single-centre approaches. 
Despite considerable efforts, few patients managed smok-
ing cessation or regular exercise in the Steno-2 study. The 
Steno-2 study also supplemented glycaemic and BP con-
trol with dietary supplements of vitamins E and C together 
with folic acid, which is not standard clinical practice. 
These approaches, however, (Steno, Bergamo) are com-
pletely impractical for normal clinical practice due to the 
intensity required to manage the needs of an ever-growing 
population.
The next challenge: defining renal endpoints 
and how to measure them
Traditionally, a change in proteinuria, a doubling of serum 
creatinine or reaching ESKD are the renal endpoints used 
to determine outcome and efficacy of treatment in renal tri-
als (Table 3).
These traditional “biomarkers” have several limitations 
(see above) and require large and costly interventional tri-
als. The trial endpoints currently used require long trials 
to assess the CV mortality and whether a progression of 
ESKD or a double of serum creatinine is reached in this 
variably progressive disease. Using these trial endpoints 
limits, the ability to determine treatment effect with no 
insight into how the natural history of the disease and its 
complications are affected, due to the longer time point sur-
rogate markers employed. This has led to suggestions of 
measuring other proteins in new clinical trials to compare 
this with albuminuria [50]. To assess whether the change 
or persistence in albuminuria continues despite the new 
intervention and compares these effects with the different 
severity of disease within the chosen population. It has also 
been suggested that an alternative surrogate endpoint could 
be a 30–40 % decrease in GFR with albuminuria defined as 
new onset, progression or regression with micro-/macroal-
buminuria, however, discussion in this area continue [67]. 
Development of new biomarkers looking at different under-
lying structural damage or pathophysiological pathways 
opens new avenues for assessing progressive DN (Table 4); 
however, how these biomarkers correlate with human his-
topathological changes is currently unknown and not rou-
tinely practiced.
Biomarkers in DN: Better than albuminuria or GFR?
The limitations of using albuminuria or GFR alone are 
apparent with their use as trial endpoints requiring fur-
ther thought. New biomarkers also have their limitations 
and may be perceived as no better than those established, 
however, using more specific markers that are specific to 
Table 3  Current renal endpoints used in trials
Trial Primary renal endpoints Effects on ACR Effects on GFR
PREVEND (Prevention of Renal and Vascu-
lar End-stage Disease Intervention trial)
CV mortality, hospitalisation for CV mor-
bidity and reaching ESKD
Decrease No change
RENAAL (see above) CV mortality, time to ESKD Decrease Decrease GFR slowed with ARB
IDNT (see above) Double serum creatinine Decrease Decrease GFR slowed with ARB
BEACON (see below) Decrease risk of ESKD or CV mortality in 
T2DM with CKD IV
Increase Increase in GFR
Table 4  Biomarkers for DN
Mechanism Potential biomarkers
Glomerular Cystatin C
Urinary Col4, transferring, caeruloplasmin, MCP-1
Tubuloepithelial NAG, NGAL, KIM-1
Urinary α1-microglobulin, L-FABP, CTGF, RBP
Oxidative stress and inflammation Urinary 8-OHdG
Serum TNFR, IL-6, TNFα
Urinary pentosidine, TNFα, α1 acid glycoprotein, VEGF, YKL-40
Endothelial dysfunction Tyrosine kinase
C-type natriuretic peptide
Genomics, proteomics and metabolomics AFF3 gene
CKD273
microRNAs Urinary or plasma miR192, miR29
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underlying glomerular or tubular dysfunction, the different 
stages of disease progression may be identified and used to 
eloquently individualise therapies.
Glomerular damage
Cystatin C is a 13.3-kDa freely filtered plasma protein that 
is catabolised by tubular cells, thereby not returning to 
the circulation and has been described as a more sensitive 
marker of renal function than serum creatinine in early DN 
[68, 69]. This marker could be adopted for trials looking at 
early DN where GFR is less sensitive.
Urinary and serum Col4 with a low molecular weight 
(LMW) of 540 kDa are elevated in DN [70]. Raised urinary 
Col4 levels occur in normoalbuminuric DN and could be 
an earlier marker than microalbuminuria of underlying glo-
merular damage [71]. However, Col4 levels decrease with 
improved glycaemic control, limiting its use [72]. In con-
trast, urinary transferrin (76.5 kDa) is a plasma protein that 
increases independently of albuminuria [73] and a predictor 
of development of microalbuminuria in normoalbuminuric 
T2DM irrespective of BP or HbA1c [74]. This may be a 
useful marker in CKD 3a disease or to determine underly-
ing hyperfiltration.
Urinary monocyte chemoattractant protein-1 (MCP-1/
CCL2) increases in macroalbuminuric but not in microal-
buminuria T2DM patients [75]. Urinary MCP-1 levels have 
been shown to correlate with DN tubulointerstitial lesions, 
fibrosis and glomerular injury [76, 77]. This biomarker has 
the potential to determine progressors, and in trials look-
ing at microalbuminuria, detection of this could be used as 
a new endpoint of predicting ongoing disease. Raised uri-
nary caeruloplasmin (132 kDa) is an acute-phase protein 
whose excretion increases in normoalbuminuric DN, but its 
usefulness is limited by its reversibility with improved gly-
caemic control [78]. Matix metalloproteinases (MMP9) are 
reported to be increased in DN where the ECM has broken 
down and there is increased cell turnover. MMP9 is also 
raised during podocyte dedifferentiation and may be used 
as an early marker of DN [79].
Tubuloepithelial makers
Trials measuring biomarkers with different underlying his-
topathologies will help develop a greater understanding of 
the occurrence of these processes and landmark disease 
processes. This will allow treatments to be specifically tar-
geted to the underlying pathways leading to these changes 
and allow them to be adapted and personalise the individu-
als, therapy to prevent progression. Tubuloepithelial mark-
ers in combination with glomerular markers may result in a 
reasonable predictive trial surrogate endpoint.
An increase in secretion or decrease in reabsorption 
of LMW plasma proteins may be detected in the urine 
reflecting tubuloepithelial cell damage. N-acetyl-β-d-
glucosaminidase (NAG) is a 140-kDa lysosomal enzyme 
in renal tubules that increases in normoalbuminuric DN 
with significantly raised levels occurring with transition 
from micro- to macroalbuminuria in T2DM [80]. Neu-
trophil gelatinase-associated lipocalin (NGAL) (25-kDa) 
protein stored in neutrophilic granules bind and transport 
small hydrophobic molecules to regulate the immune sys-
tem and apoptosis [81]. Raised levels of NGAL are seen in 
the hyperfiltration stage of DN with a lowering of GFR and 
a raised cystatin C when compared with healthy controls 
[82]. When adjusted for BP, HbA1c and duration of diabe-
tes, the difference is no longer significant. Kidney injury 
molecule-1 (KIM-1) is a type-1 cell membrane glycopro-
tein on the apical membrane of the proximal tubule that 
increases with tubular damage in DN [83]. Hyper-filtration 
in T2DM results in raised urinary levels of KIM-1; how-
ever, these are decreased with RAAS blockade limiting its 
use to a marker of active tubular injury [84].
Urinary connective tissue growth factor (CTGF) and 
TGF-β are increased in micro- and macroalbuminuric DN 
[85, 86] and may reflect the occurrence of underlying fibro-
sis that may be used as a marker for disease progression; 
15-kDa intracellular carrier protein liver-type fatty acid 
binding protein (L-FABP) found in the liver and proxi-
mal tubular cells is a marker of structural and functional 
renal tubular damage. This increases with diabetes and 
albuminuria [87]. Again, its use is limited with the use of 
RAAS blockade. In contrast, urinary retinal binding protein 
(RBP), a 21-kDa freely filtered microprotein that is almost 
completely reabsorbed in the proximal tubules, is a highly 
sensitive marker of early DN with its excretion reflecting 
damage in normoalbuminuria [88]. RBP has also been cor-
related with micro- and macrovascular complications of 
T2DM. Studies suggest urinary α1-microglobulin (A1M), a 
26-kDa microprotein similar to RBP, may be used to deter-
mine tubular dysfunction in early DN [89].
Markers of oxidative stress and inflammation
ROS are produced with hyperglycaemia and contribute to 
diabetic complications via the accumulation of sorbitol and 
the formation of advanced glycation end products (AGE) 
and activation of protein kinase C pathways. Enzyme cleav-
age of ROS-induced 8-hydroxylation of guanine base from 
nuclear and mitochondrial DNA results in 8-oxo-7, 8-dihy-
dro-2-deoxyguanosine (8-OHdG) as a product of oxida-
tive DNA damage in the urine [90]. These urinary levels 
may be used to determine early underlying oxidative stress 
damage.
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Serum and urinary TNFα levels increase with micro- and 
microalbuminuria in T2DM [91]. TNF receptors (TNFRs) 
1 and 2 mediate the effects of TNFα. Serum levels of these 
membrane bound receptors correlate with GFR in DN inde-
pendent of albuminuria [92]. Raised baseline serum TNFR 
in patients with DM has predicted progression of CKD 3–5 
independently of albuminuria after 12 years [93, 94] and is 
a promising biomarker of early DN.
Serum interleukin-6 (IL-6) increases with albuminuria 
and in those with underlying glomerular basement mem-
brane thickening [95, 96]. Urinary orosomucoid or α1 acid 
glycoprotein (AGA) is a polypeptide released in response 
to inflammatory cytokines IL-6 and TNFα and reported to 
be raised in CVD, lung cancer and DM [97]. Urinary levels 
of vascular endothelial growth factor (VEGF) (an angio-
genic inducing cytokine related to endothelial permeabil-
ity) are increased in normoalbuminuric DN [98].
Endothelial dysfunction
YKL-40 is a pro-inflammatory marker independently asso-
ciated with albuminuria in early T2DM [99, 100]. High 
levels have been reported to predict CV mortality [101]. 
Tyrosine kinase is predominantly found in endothelial 
cells and has been described as a biomarker for underlying 
angiogenesis pathways [102]. It binds to angiopoietin of 
endothelial cells to induce angiogenesis. C-type natriuretic 
peptide (CNP) arises from damage to the vascular endothe-
lium and is a predictor of GFR decline [103].
Genomics, proteomics and metabolomics
The development of DN arises from a combination of 
genetic and environmental factors. Genome-wide associa-
tion scans have been widely used to determine gene vari-
ants predisposing to DN [104]. AFF3 gene on chromo-
some 15 has been described in T1DM with DN and also 
seen as an inducer of TGF-β fibrosis in cultured epithelial 
cells [105]. By contrast, proteomics will provide multi-
ple markers of DN combining cytokines, collagen frag-
ments and RBP [106–108]. A panel of 273 urinary peptides 
(CKD273) was reported to be specific and sensitive for the 
early detection of DN [109]. The risk of progression was 
identified with this panel in a cohort of 35 patients with 
DM and normoalbuminuria followed up for 5 years [110]. 
CKD273 has subsequently been validated in a multicentre 
study that distinguished DN from controls with a factor 
cut-off, thereby determining individuals at a high risk of 
progressing [110, 111].
There is a paucity of studies in metabolomics whereby 
the measure of cellular function using LMW intermedi-
ate and end products of the cell reflect the genomic, tran-
scription and proteomic function of the cell affected by the 
underlying disease pathology [112]. Changes have been 
detected in the phospholipid and amino acid metabolism 
of normoalbuminuric diabetic patients and healthy controls 
[113]. Consideration of the benefit of renal biopsy in trial 
patients to assess the effect of treatment and that of disease 
on the biomarkers used may need to be taken prior to deter-
mining the accuracy of these markers to reflect underlying 
disease processes in man.
MicroRNAs
MicroRNAs (miR) are short non-coding RNAs of 20–22 
nucleotide length that may be measured in plasma and 
urine and use posttranscriptional mechanisms to result in 
gene silencing via the reduction of translation or induction 
of target degradation [114, 115]; 60 % of the human pro-
tein coding genes are thought to be regulated by miR [116]. 
miR192 upregulates miR216a/217 and miR200b/c that 
increases collagen expression stimulated by TGF-β miR-
mediated mechanism. This may promote autoregulation of 
TGF-β1 seen in mouse mesangial cells and renal glomeruli 
of mouse models of DN [117, 118]. Mice with deletion of 
miR192 in vivo were protected from DN [119]. miR192 
promoter has also been seen to be regulated by Smads via 
histone acetylation via TGF-β in renal cells [120, 121]. The 
downregulation of miR29 correlated with an increase in 
collagens I, III and IV in ApoE-/- diabetic mouse kidneys 
in proximal tubuloepithelial cells, mesangial cells, podo-
cytes and TGF-β. miR192 promotes fibrosis with miR29 
being anti-fibrotic [120, 122]. A single study, however, 
showed in patients with diabetes a decrease in miR192 was 
associated with increased severity of fibrosis and DN; how-
ever, this study did not determine normal levels of miR192 
in healthy fibrosis [123].
The miRs levels vary from cell type to cell type, and 
thus, the overall levels in a condition need to be determined 
before this can be used as a tool to predict progression of 
DN. Urinary miR levels have been measured together with 
circulating levels in patients with CKD and may prove 
to be useful biomarkers of disease [124]. Potential anti-
miR target drugs with conventional therapy may be a new 
approach in the management of DN.
Recently, Pena et al. [103] published an observational 
study looking at the value of a panel of 28 serum biomark-
ers on predicting a decline in GFR in 82 patients with a 
4-year follow-up. The two statistical models determined 
a change of <3 ml/min/1.73 m2/year with the chosen bio-
markers reflecting different pathways previously reported 
to be involved in DN. Other studies have used urinary 
biomarkers [125] or a combination of plasma and urinary 
biomarkers [126]; however, these panels have not been 
validated or used in a mixed population of T1/T2DM with 
varying degrees of albuminuria.
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Another approach to the selection of biomarkers has 
recently been reported by Lambers Heerspink et al. [127]. 
The SysKid consortium performed a comparison of sys-
tematic analysis of molecular pathways for DN previously 
described in the literature with a systematic analysis of the 
molecular pathways and mode of action of a drug of inter-
est, such as ACEi. The overlapping molecular pathways were 
used to identify biomarkers similar to both and provide a basis 
to study subgroups and identify these as phenotype profiling. 
This novel approach may identify within-groups genetic pol-
ymorphisms that determine whether a specific group within 
the DN spectrum will have a more effective response to the 
therapy and thereby enhance personalised therapies to preci-
sion medicine. This data analysis combines genomic, prot-
eomic, metabolomic and transcriptomic molecular pathways 
and closely centres around the effects of new therapies to pro-
vide biomarkers and maybe useful when monitoring the treat-
ment effect of certain therapies in the future once validated.
The pathogenesis of DN is increasingly accepted as 
involving multiple mechanisms [24], and in response, there 
are now a host of novel approaches to DN (Table 5). New 
therapeutic strategies are emerging with some currently 
being conducted in small trials with some promising initial 
results [128–131].
Novel interventions to tackle the problem
Antioxidants and anti‑inflammatories
Oxidative stress and inflammation have been increasingly 
described to be active in the progression of CKD, in par-
ticular in DN [128, 132, 133]. Nuclear-1-factor (erythroid-
derived 2)-related factor 2 (Nrf2) is a transcription factor 
driving the antioxidant response, impaired in experimental 
animal models of CKD [134]. Bardoxolone methyl is a syn-
thetic triterpenoid that activates the Nrf2 pathway, restoring 
antioxidant response. Early human studies with T2DM and 
CKD stage 3b–4 reported reductions in serum creatinine 
concentration with bardoxolone methyl for up to 52 weeks 
[135, 136]. Subsequently, the BEACON trial was designed 
to determine whether bardoxolone methyl reduced the risk of 
ESKD or cardiovascular mortality in T2DM with CKD stage 
4 [137]. A significant increase in GFR, BP, body weight and 
urinary ACR was seen in the bardoxolone methyl compared 
with the placebo group. However, the BEACON trial was 
terminated following a median follow-up of 9 months after 
43 patients receiving bardoxolone methyl developed ESKD 
and increased cardiovascular morbidity and mortality (from 
any cause) were observed in the intervention arm when com-
pared to placebo, with “heart failure” being a prominent sig-
nal. It is postulated that the side effects arose due to a longer 
exposure period to the drug in individuals with a more severe 
form of CKD; however, further detailed analysis is pending. 
There were suggestions that bardoxolone was toxic in mouse 
models of DN that were not translated to the initial human 
study although the improvement in GFR in the initial study 
remains unexplained [138]. Novel Nrf2 activators are in the 
pipeline, and future studies will determine their potential 
benefit in the clinical setting [139–141].
Smaller studies have looked at other targets to determine 
whether there is any benefit to combined treatment with 
RAAS blockade (Table 5). Pyridoxamine (vitamin B6) has 
been shown in animal studies to be a natural inhibitor of 
AGE with additional reductions in albuminuria and pres-
ervation of renal function [142, 143]. Lewis et al. [144] 
conducted a randomised double-blind placebo-controlled 
trial in T2DM treated with pyridoxamine for a year, but the 
results were negative.
Pentoxifylline is a methylxanthine derivative with inhib-
itory actions against TNF-α. The PREDIAN trial shows 
significant reductions in proteinuria (p < 0.01) and preser-
vation of renal function with pentoxifylline in combination 
with ACEi/ARB therapy compared to ACEi/ARB therapy 
alone (p < 0.001) in CKD stages 3/4 and T2DM [145].
Silymarin is a herbal drug with antioxidant, anti-inflam-
matory and anti-fibrotic properties. It is the active constit-
uent of the seed Silybum marianum, otherwise known as 
milk thistle. In a small study, silymarin reduced albuminu-
ria, urinary TNFα and malondialdehyde—a marker of oxi-
dative stress in patients with DN [146].
Macrophage recruitment into adipose tissue is thought 
to contribute to insulin resistance. The development of a 
CCR2/MCP-1 antagonist in animal studies was accompa-
nied by better glycaemic control while decreasing glomeru-
losclerosis and albuminuria in diabetic mice [147]. More 
recently, the results of a randomised placebo-controlled 
study in 89 T2DM normoalbuminuric patients were given 
the CCR2 antagonist has shown improved glycaemic con-
trol while being generally well tolerated [148].
Anti‑fibrotics
Endothelin-1 has established pro-fibrotic effects within the 
kidney [149] following activation of endothelin-1A recep-
tors leading to renal cell injury, inflammation and fibro-
sis. Endothelin is raised in CKD with endothelin receptor 
antagonists reported to ameliorate these effects in experi-
mental models of CKD [150]. Endothelin-1A antagonist 
(atrasentan) with ACEi/ARB significantly reduced albu-
minuria in a recent randomised controlled trial in T2DM; 
however, heart failure and fluid overload were the main 
side effects limiting this treatment [151]. A novel endothe-
lin antagonist (avosentant) is currently been tested for renal 
and cardiovascular endpoint in patients with T2DM and 
proteinuria as add-on to RAAS inhibition.
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Daglutril is a combination between endothelin-con-
verting enzyme and neutral endopeptidase inhibitor drugs 
with potent anti-hypertensive actions that are synergistic 
with RAAS blockade [152]. Minimal facial and peripheral 
oedema was thought to arise from the inhibitions of the 
neutral endopeptidase that increase natriuretic peptides, 
bradykinin and substance P. This 8-week study showed 
effects on BP alone. Longer studies will determine any 
potential renoprotective effect of this drug in diabetes.
The anti-fibrotic pirfenidone inhibits TGF-β in animal 
models [131]. A small trial showed an improvement in 
GFR at 1 year, but gastrointestinal symptoms and fatigue 
were common in this small study [153]. Interestingly, the 
benefit in GFR was seen using a lower rather than a higher 
dose of pirfenidone and further studies are required. 
CTGF has been shown to have an important effect on 
the development of renal fibrosis in DN [154]. The anti-
CTGF monoclonal antibody has been given to 24 micro-
albuminuric T1DM or T2DM with the effect of reducing 
albuminuria up to a year later; however, a larger trial is 
pending [130]. Recently, anti-TGF-β1 therapy failed to 
slow disease progression in patients with advanced DN 
in a randomised, double-masked, phase 2 dose-ranging 
study [155].
Vitamin D deficiency has been shown in animal stud-
ies to contribute to the severity of albuminuria, podocyte 
effacement and increased glomerular basement membrane 
[156]. Replacement with an active analogue reduces pro-
teinuria, interstitial fibrosis while improving renal func-
tion [157, 158]. A meta-analysis of vitamin D analogues in 
humans has shown a reduction of proteinuria in combina-
tion with RAAS blockade using an ACEi/ARB [159].
An increase in the expression of VEGF has been 
described in renal biopsies with DN and is thought to con-
tribute to albuminuria and glomerulosclerosis [4, 34]. Anti-
bodies against VEGF have shown a reduction in the histo-
logical features of DN in diabetic rats with a decrease in 
albuminuria [160], and may be a potential future treatment.
Anti‑proteinurics
Octreotide is a somatostatin analogue that decreases 
mesangial expansion and albuminuria in DM animal mod-
els [161]. A small study showed an improvement in GFR, 
ACR and no change in renal biopsy volume in T1DM given 
octreotide [162], with a further study showing a reduction 
of albuminuria following 6 months of treatment [163].
Recently, subcutaneous adrenocorticotrophic hormone 
gel was given to patients with DN with nephrotic range 
proteinuria; this treatment achieved a significant reduction 
in proteinuria after 6–12 months which continued for a year 
following cessation of treatment. Renal function remained 
stable in these studies [164].
Doxycycline is a tetracycline antibiotic that inhibits 
matrix metalloproteinases (MMPs). A decrease in pro-
teinuria was seen at 6 months in combination with RAAS 
blockade and anti-hyperglycaemic agents in a small cohort 
[165]. The cessation of doxycycline resulted in the return of 
previous levels of albuminuria. Allopurinol used in asymp-
tomatic hyper-uricaemic patients with DN was seen to 
reduce albuminuria in 4 months of treatment in this small 
RCT of 40 patients and could be used as an adjunct with 
RAAS blockade [166]. More recently, the PERL is under-
way recruiting patients with T1DM and CKD stages 1–3 
to be given allopurinol for a 3-year period, and the results 
are awaited [167]. However, allopurinol has recently been 
reported in T2DM to significantly decrease serum uric acid, 
ACR, serum creatinine and improve GFR compared to the 
conventional treated arm [168].
Current limitations and challenges of regulatory 
requirements for study of late‑stage DN
The old adage ignorance is bliss may be applied with 
the current belief that there is adequate understanding in 
the field of the pathogenesis of this disease that has been 
described since Egyptian times [169] and continues to 
afflict millions. The major limitation with studies in this 
field fundamentally lies around the lack of a good bio-
marker to determine disease stage and without establish-
ing the pathophysiology of this disease to a higher-degree 
primary prevention, and early intervention trials are made 
incredibly difficult. Establishing whether glomerular pro-
cesses versus tubular damage versus ROS/other path-
way activation occur first will more effectively allow new 
emerging therapies to be personalised to the individual 
with monitoring, using a panel of more sensitive markers 
reflecting underlying damage or activation of established 
pathways. Further validation of biomarkers arising from the 
comparison of molecular pathways of certain DN pheno-
types whose genetic polymorphisms may make them more 
susceptible to certain drug therapies may provide a plat-
form for precision medicine in the future.
The emergence of new biomarkers should be consid-
ered to run in parallel with albuminuria in trials allowing 
for increased sensitivity and comparison to the classical 
‘normo-, micro- and macroalbuminuria’ while we increase 
our understanding. Subsequently, biomarkers that have 
been discovered depicting early or later stages should be 
employed to allow treatment effects to be determined. The 
biomarkers should be used to assess the different CKD 
stages occurring within those with DN and arguably the 
change of GFR may be a better comparator for new bio-
markers. The treatments should then be used to target the 
area the biomarker suggests is the most likely active cause 
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of damage. Mann et al. [170] recently refer to the benefit 
of using a roadmap for studies involving a number of dif-
ferent stakeholders such as clinicians, statisticians, patient 
groups, health insurance and pharmaceutical companies, 
biobanks and regulatory agencies, to help avoid delays in 
the discovery and introduction of therapies and biomarkers 
to the clinic.
Without the roadmap approach, funding inevitably lim-
its long-term studies and emphasises the importance of 
multicentre trials whereby large groups of people with the 
same CKD stage can be compared. The additional chal-
lenge is that of the different rates of progression affecting 
those with DN that may be in part influenced by whether 
patients are T1DM or T2DM. The final common pathway 
of fibrosis affects both; however, it is well established that 
the autoimmune T1DM differs from the metabolic pheno-
type of those with T2DM and insulin resistance rather than 
autoimmune destruction of the pancreatic β-islet cells. It 
would seem more prudent to continue to separate trials for 
type of diabetes or to conduct trials with a subgroup analy-
sis of T1DM and T2DM within the CKD stages to ascer-
tain whether the results and biomarkers behave in the same 
manner or differ, thereby making markers more robust 
while more importantly allowing clarity as to what popula-
tion benefits from a particular new therapy.
Where does this leave the researcher?—to investi-
gate the pathophysiology and markers of disease to deter-
mine new therapeutic targets with this understanding. 
Great attention to differences seen in translational treat-
ments is important in view of the recent experience with 
bardoxolone.
Where does this leave the clinician?—to be aware of 
changes occurring in the field and to actively enrol appro-
priate patients into trials where new therapies are being 
monitored with more sensitive markers. Both researcher 
and clinician need to urgently review the current primary 
endpoints of: doubling of serum creatinine, ESKD or death 
used in this chronic disease especially with early inter-
vention trials. For trials conducted in late-stage DN, all 
patients should be monitored in specialised DN clinics. 
In addition, clinicians need to establish within their coun-
tries health service infrastructure how patients may be fol-
lowed up with either dedicated DN clinics or primary care 
facilities to record how effective therapies are following the 
completion of initial funding for the trial period. We would 
challenge the cessation of follow-up for these patients until 
we are able to determine outcome and would advocate a 
national database for DN. Larger multicentre trials will nat-
urally enhance our understanding in this field and should be 
increasingly considered in view of the worldwide increas-
ing incidence of this devastating disease.
More importantly, where does this leave the patients?—
in a new era, an awakening leading to personalised 
treatment goals according to the progression or stability 
of their disease with the hope of preventing progression to 
ESKD.
Final conclusions and future strategies for clinical 
research
RAAS blockade alone is insufficient in preventing the pro-
gression of diabetic kidney disease in many patients. Good 
glycaemic control is important in reducing mortality in this 
cohort of patients; however, very tight glycaemic control 
may be deleterious [171]. No benefits have been reported 
for aspirin in the primary prevention of cardiovascular mor-
tality in patients with diabetes; however, it is recommended 
in those who have had a cardiovascular event. Statins may 
reduce major cardiovascular events without affecting the 
progression of renal disease.
There are clear and urgent needs to improve our under-
standing of the pathogenesis of DN, identify new inter-
ventional therapeutic targets and develop new markers of 
disease progression. The new targets for intervention need 
to be tested using a melange of old and new markers of 
disease progression to maximise the chance of detecting 
useful biological signals. New therapeutics will become 
available presenting the challenge of when to begin these 
treatments and how to tailor treatments to the individual. 
Some of these agents such as vitamin B6, pentoxifylline 
and vitamin D are readily available and may be introduced 
to current therapy strategies. Whether any of these novel 
approaches can usefully reduce mortality remains to be 
determined.
This review emphasises the need for physicians to look 
anew at treatment strategies for this high-risk group and 
perhaps employ the use of multiple treatment strategies 
beyond that of RAAS blockade. We challenge the current 
renal endpoints used and how we continue to conduct trials. 
The need for new therapeutic agents, coupled with refined 
and more sophisticated trial renal endpoints using new bio-
markers, is both obvious and urgent requiring our commu-
nity to reunite in order to advance treatment strategies in 
this field.
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